Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease

US Patent 10377768 · Granted Aug 13, 2019

Estimated economic value: $124,537,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

IL4I1 inhibitors and methods of use2025
1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharm2025
N-heteroaryl indazole derivatives as LRRK2 inhibitors, pharmaceutical compositio2024
Compounds for modulating mitochondrial function2024
Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inh2022
Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,32022
Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmac2021
Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmac2021
Compounds for modulating mitochondrial function2021
Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharma2021
Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharma2021
Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine2021